XWAR
MOC
Market cap41mUSD
Oct 09, Last price
6.66PLN
1D
-0.45%
1Q
12.50%
IPO
-77.03%
Name
Molecure SA
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
8.10%
Rev. gr., 5y
-49.35%
Revenues
0
-100.00%
Net income
-16m
L-49.86%
CFO
-19m
L-65.94%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
Key people
Chairman of the Supervisory Board
Marcin Jan Szumowski
Chairman of the Management Board, Chief Executive Officer
Mariusz Ryszard Gromek
Vice Chairman of the Supervisory Board
Slawomir Piotr Broniarek
Finance Director, Member of the Management Board · since 2016
Marta Borkowska
Director of Operations
Karolina Dzwonek
Vice President Biology
Adam Golebiowski
Vice President Research (Director of Medical Chemistry)
Jacek Olczak
Vice President Chemistry
Nicolas Beuzen
Business Development Director
Pawel Dobrzanski
Senior Scientific Director, Oncology
Henryk Gruza
Member of the Supervisory Board · since 2018
Member of the Supervisory Board · since 2018
Headquarters & legal address
Warszawa Żwirki i Wigury 101
Warszawa, 14 02-089
PL
Warszawa, 14 02-089
PL
Previous name
OncoArendi Therapeutics Spółka Akcyjna
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||